3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
NET
1
Gastrointestinal
1
Endocrine
1
Conditions
Stomach Neoplasms
1
Pancreatic Neoplasms
1
Neuroendocrine Tumors
1
Neoplasms, Unknown Primary
1
Gastrointestinal Stromal Tumors
1
Gastrointestinal Neoplasms
1
Esophageal Squamous Cell Carcinoma
1
Colorectal Neoplasms
1
Biliary Tract Neoplasms
1
Interventions
Trastuzumab
2
Quality of Life
2
Fluorodeoxyglucose F18
2
tislelizumab
1
tipifarnib
1
surufatinib
1
regorafenib
1
milademetan
1
lutetium Lu 177 dotatate
1
fludarabine phosphate
1
fludarabine
1
entinostat
1
copper dotatate CU-64
1
Surveys and Questionnaires
1
Ritonavir
1
Radiotherapy
1
Poly(ADP-ribose) Polymerase Inhibitors
1
Patient Reported Outcome Measures
1
PM 01183
1
Oxaliplatin
1
N-Ac-CHAVC-NH2
1
Molecular Diagnostic Techniques
1
Melphalan
1
Magnetic Resonance Spectroscopy
1
Lutetium-177
1
Lutetium
1
Leucovorin
1
Irinotecan
1
Interleukin-12 Subunit p35
1
Interleukin-12
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Stomach Neoplasms
×
Poly(ADP-ribose) Polymerase Inhibitors
×
Endocrine
×
Clear all
NCT04584008
2024-10-15
VISIONARY
Peking University
Phase NA
Active not recruiting
600 enrolled